Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHepQuant, LLC
About this trial
This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clinic at 1, 3, 6, and 12 months. At each of these visits, participants will undergo a HepQuant DuO test and other standard tests. In addition, the study team will ask about a participant's alcohol use, symptoms, and quality of life.
Eligibility criteria
Qualifiers
adult with a clinical diagnosis of liver disease due to alcohol who have acute hepatic decompensation.
Disqualifiers
Clinical diagnosis of liver disease with an etiology other than alcohol liver disease unless it is a combined clinical diagnosis of ALD and NASH.
patients with solid organ malignancy.
patients with other disease affecting the liver including autoimmune, drug-related liver injury, hemochromatosis or Wilson's disease
pregnancy
Trial design
Treatments tested in this trial
- HepQuant DuO Test
Treatment groups
No treatment groups listed
Sponsors and collaborators
HepQuant, LLC
Lead sponsor
Leland Stanford Junior University
Collaborator
Source ClinicalTrials.gov